Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences


Ormeci N., Sezgin O., Karaali R., AYGEN B. , Turan D., Yaras S., ...Daha Fazla

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.31, ss.534-539, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 31 Konu: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1097/meg.0000000000001334
  • Dergi Adı: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
  • Sayfa Sayıları: ss.534-539

Özet

Introduction Both hepatitis C virus infection (HCV) and chronic kidney disease (CKD) have been comorbid illnesses with increasing morbidity and mortality. The present study was conducted to present real-life experiences about treatment of HCV and CKD with a fixed-dose combination of paritaprevir 150 mg/day, ritonavir 100 mg/day as a booster, ombitasvir 25 mg/day, and dasabuvir 250 mg twice/day, the PROD regimen.